The Law of Large Numbers tells us that the odds of investment success improve when a company addresses a mass market, and this is a theme you will read about in nearly every issue of Cabot Small-Cap Confidential. In this issue, the market being addressed is women (who account for over half the population of the planet), and the condition being targeted is the growth of uterine fibroids, a medical phenomenon that traditionally leads to a hysterectomy. BioSphere, our featured stock this month, has a treatment that blocks blood flow to uterine tumors and fibroids, and the increasing adoption of this minimally invasive procedure promises improved health for hundreds of thousands of women as well as reduced expense for insurers. To investors who get on board in the months ahead, the long-term result should be big profits.
